Figures at a glance

Figure 1

Figure 2

Figure 3

Figure 4

FIGURE 1

Figure 1: : Hepatic Steatosis Over Time
This chart shows the levels of hepatic steatosis in the control group, melatonin group, and combined treatment group over a period of 16 weeks. The chart indicates that both melatonin and the combined treatment significantly reduce hepatic steatosis compared to the control group.

FIGURE 2

Figure 2: ER Stress Markers
This bar chart illustrates the relative expression levels of ER stress markers GRP78 and CHOP across the control, melatonin, and combined treatment groups. The combined treatment group shows the lowest levels of these markers, suggesting reduced ER stress.

FIGURE 3

Figure 3: Gut Microbiota Composition
This chart presents the relative abundance of various bacterial groups in the gut microbiota for the control, melatonin, and combined treatment groups. The beneficial bacteria (Bifidobacterium and Lactobacillus) are more abundant in the melatonin and combined treatment groups, indicating a healthier gut microbiota composition.

FIGURE 4

Figure 4: Cancer Risk Assessment: Histopathological and Molecular Analysis
The chart a clear depiction of the cancer risk assessment results, highlighting histopathological and molecular analysis: Preneoplastic Lesions: The blue bars indicate the number of preneoplastic lesions observed in the control, melatonin, and combined treatment groups. There is a significant reduction in lesions in the melatonin and combined treatment groups compared to the control group. DNA Damage: The red line represents the relative levels of DNA damage, showing lower levels in the treated groups, especially in the combined treatment group. Tumor Suppressors: The green line shows the relative expression levels of key tumor suppressors (p53, Rb), which are upregulated in the treated groups, indicating enhanced genomic stability. Oncogenes: The purple line indicates the relative expression levels of oncogenes (c-Myc, Ras), which are downregulated in the treated groups, suggesting a reduced risk of cancer development. This comprehensive visualization underscores the efficacy of melatonin and the combined treatments in mitigating NAFLD and reducing liver cancer risk.